M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal BioPharma DiveThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.Rare DiseaseRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) BioPharma Dive The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore projectNext: Decoding Medicare Advantage Coding Intensity Related Stories M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026 M&A / Deals Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics pharminent July 20, 2026 M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover pharminent July 16, 2026
